SCHEMBL18077992

SCHEMBL18077992

Cc1ccc(-c2noc([C@H](CC(N)=O)NC(=O)N[C@H](CO)C(=O)O)n2)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VSIR Q9H7M9 3/20 0.48
CD274 Q9NZQ7 2/20 0.48
TSHR P16473 3/20 0.35
LMNA P02545 3/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
TP53 P04637 1/20 0.35
PDCD1LG2 Q9BQ51 1/20 0.33
HTT P42858 2/20 0.33
KMT2A Q03164 2/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
PKM P14618 1/20 0.32
HPGD P15428 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18077949 0.88 NPSR1 (0.47) VSIRCD274TSHRLMNAALDH1A1
SCHEMBL19867090 0.86 CD274 (0.61) VSIRCD274TSHRLMNANPC1
SCHEMBL18077934 0.86 CD274 (0.61) VSIRCD274TSHRLMNANPC1
SCHEMBL19981151 0.77 SMN1; SMN2 (0.41) TSHRLMNANPC1RAB9AALDH1A1
SCHEMBL21738486 0.76 CD274 (0.73) VSIRCD274PDCD1LG2CA2CA1
SCHEMBL16557026 0.76 CD274 (0.73) VSIRCD274PDCD1LG2CA2CA1
SCHEMBL19981309 0.76 NPC1 (0.39) TSHRLMNANPC1RAB9AALDH1A1
SCHEMBL18078014 0.76 NPC1 (0.38) TSHRLMNANPC1RAB9AALDH1A1
SCHEMBL16557030 0.75 CD274 (0.68) VSIRCD274PDCD1LG2
SCHEMBL18735674 0.75 CD274 (0.68) VSIRCD274PDCD1LG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180044329-A1 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-02-15 US disclosed
US-20180044329-A1 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-02-15 US disclosed
WO-2016142886-A2 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2016-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044329-A1 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS PDCD1, CD274, PDCD1LG2 VSIR 2158/4885CD274 2/4885TSHR 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.